TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 10)
1.1 COVID-19 HEALTH ASSESSMENT
1.2 COVID-19 ECONOMIC ASSESSMENT
1.3 COVID-19 IMPACT ON THE ECONOMY—SCENARIO ASSESSMENT
2 COVID-19: DEVELOPMENT OF VACCINES (Page No. – 16)
2.1 VACCINES
2.1.1 CURRENT PIPELINE OF VACCINES
2.1.2 COMPETITIVE LANDSCAPE (TOP PLAYERS DEVELOPING VACCINES)
2.1.2.1 Viewpoint on the COVID-19 pipeline
2.1.3 MACROECONOMIC INDICATORS
2.1.3.1 Drivers
2.1.3.1.1 Increasing prevalence of infectious diseases
2.1.3.1.2 Growing funding for vaccine development
2.1.3.2 Restraints
2.1.3.2.1 High cost of vaccine development
2.1.3.2.2 Drugs and alternate therapies under development
2.1.3.2.3 Compassionate use
2.1.3.2.4 Immunization strategies
2.1.3.3 New opportunities
2.1.3.3.1 Collaborations among global organizations and vaccine manufacturers
2.1.3.4 Challenges
2.1.3.4.1 Herd immunity
2.1.4 POST-COVID-19 VACCINE APPROVAL SCENARIO
2.1.4.1 Challenges in vaccine approval/production/supply
2.1.4.1.1 Are companies taking enough advantage of artificial intelligence (AI) to fast track vaccine/drug approval? (medium criticality)
2.1.4.1.2 Can production for pandemics be a challenge? (high criticality)
2.1.4.1.3 The world needs a vaccine but who needs it the most?(medium criticality)
2.1.4.1.4 Global organizations are expediting clinical research, but will site and logistical challenges cause delays?(high criticality)
2.1.4.2 Strategies to overcome challenges
2.1.4.2.1 Collaborations among global organizations
2.1.4.2.2 Establishing reliable supply chains
2.1.4.2.3 Historic examples (SARS, MERS, EBOLA, and H1N1)
2.1.4.2.4 Supply and Demand Issues during H1N1 Vaccination
2.1.4.2.5 Challenges in Supply Projections
2.1.4.2.6 Recommendations from the H1N1 Vaccination Program
2.1.4.2.7 Strategies adopted by several pharmaceutical companies to combat the H1N1 pandemic
2.1.4.2.8 Historic examples
2.1.4.2.9 New strategies
2.1.4.3 COVID-19 VACCINES MARKET (OPTIMISTIC, PESSIMISTIC, AND REALISTIC)
2.1.4.3.1 Market size estimation for optimistic scenario
2.1.4.3.2 Market size estimation for realistic scenario
2.1.4.3.3 Market size estimation for pessimistic scenario
3 COVID-19: DEVELOPMENT OF THERAPEUTIC DRUGS (Page No. – 42)
3.1 COMPETITIVE LANDSCAPE (DRUGS MARKET)
3.1.1 TOP PLAYERS INVOLVED IN THE DEVELOPMENT OF DRUGS FOR COVID-19
3.1.1.1 Sanofi and Regeneron Pharmaceuticals
3.1.1.2 Oncoimmune
3.1.1.3 Gilead Science
3.1.1.4 Sanofi and the National Institute of Respiratory Diseases (Mexico)
3.1.1.5 Roche
3.1.1.6 CytoDyn
3.1.1.7 Merck KGaA
3.1.1.8 Janssen Pharmaceuticals
3.1.1.9 Masterlek
3.1.1.10 Fujifilm
3.1.1.11 Ridgeback Biotherapeutics LP
3.1.1.12 AbbVie
3.1.1.13 Viewpoint on COVID-19 therapeutic drug pipeline
3.1.1.14 Impact of COVID-19 on other products in the portfolio/other under-development products
3.1.2 MACROECONOMIC INDICATORS
3.1.2.1 Drivers
3.1.2.1.1 Alternate therapies targeting COVID-19
3.1.2.1.2 Adoption of organ-on-chip models in the development of drugs targeting COVID-19
3.1.2.1.3 Compassionate use
3.1.2.1.4 Collaborations and other developments promoting COVID-19 drugs
3.1.2.2 Restraints
3.1.2.2.1 Herd immunity and new vaccines under development
3.1.2.2.2 Uncertainty in the efficacy and side effects of repurposed malaria drugs targeting COVID-19
3.1.2.3 New opportunities
3.1.2.3.1 Adoption of new tools to expedite drug discovery
3.1.2.3.2 Investments in real-world evidence by pharmaceutical companies
3.1.2.4 Trends
3.1.2.4.1 Changes in ipr to promote the supply of essential drugs and medical supplies
3.1.3 POST COVID-19 DRUG APPROVAL SCENARIO
3.1.3.1 Challenges in drug approval/production/supply
3.1.3.1.1 In the case of treatments being available for COVID-19, will they be available to the people in need? (high criticality)
3.1.3.1.2 Orphan drug status, market exclusivity – boon or bane?(medium criticality)
3.1.3.1.3 The world needs drugs targeting COVID-19. but who needs it the most (high criticality)
3.1.3.2 Strategies to overcome challenges
3.1.3.2.1 Production turbocharge of COVID-19 hopeful drugs
3.1.3.2.2 Accelerated approvals
3.1.3.2.3 Drug manufacturers initiating programs to increase the market access of COVID-19 drugs
3.1.3.2.4 Historic examples (SARS, MERS, EBOLA, and H1N1)
3.1.3.2.5 New strategies
3.1.3.3 Strategies to ramp up production at pandemic level
3.1.3.3.1 Establishing stable supply chains to ramp up production of drugs
3.1.3.3.2 Creating external manufacturing networks
3.1.4 COVID-19 DRUGS MARKET ESTIMATION
3.1.4.1 Epidemiology model (assumption basis)
3.1.4.2 COVID-19 drugs market (optimistic, realistic, & pessimistic scenarios)
3.1.4.2.1 Market size estimation for optimistic scenario
3.1.4.2.2 Market size estimation for realistic scenario
3.1.4.2.3 Market size estimation for pessimistic scenario
